News Column

Researchers at University of Cairo Have Reported New Data on Recombinant Granulocyte Colony Stimulating Factor (Chromatographic and electrophoretic...

July 23, 2014



Researchers at University of Cairo Have Reported New Data on Recombinant Granulocyte Colony Stimulating Factor (Chromatographic and electrophoretic assessment of Filgrastim biosimilars in pharmaceutical formulations)

By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Proteins have been presented. According to news reporting from Cairo, Egypt, by NewsRx journalists, research stated, "An orthogonal testing protocol was developed and validated to assess the quality of Filgrastim biosimilars. Results were compared to those obtained from the innovator product."

The news correspondents obtained a quote from the research from the University of Cairo, "Initial screening was carried out using reducing and non-reducing gel electrophoresis. RP-LC was employed for the determination of Filgrastim in the presence of its oxidative degradation products. SEC and CIEF were used under non-denaturing conditions to reveal high molecular weight and charged impurities, respectively. RP-LC assay was found accurate (99.78 +/- 0.89) and precise over a linear concentration range of 9.38-300.00 mu g/ml with a LOD of 8.26 mu g/ml(0.44 mM). SEC was carried out over a molecular weight range of 5.0-150.0 kDa. CIEF was optimized using neutrally coated capillaries over a wide-range pH gradient (pH 3.0-10.0). Differences between the studied products were revealed using all these techniques. Impurities above the acceptable limits were detected in both biosimilar products. CIEF revealed heterogeneity in the active ingredient that has not been investigated by the manufacturers. Correlation of the obtained results indicated the presence of not only product-related impurities, but also process-related impurities. Results confirmed the need for in-house validated orthogonal testing protocols to be developed by local regulatory authorities."

According to the news reporters, the research concluded: "This should prevent access of substandard biosimilars to price-sensitive markets."

For more information on this research see: Chromatographic and electrophoretic assessment of Filgrastim biosimilars in pharmaceutical formulations. Journal of Pharmaceutical and Biomedical Analysis, 2014;97():72-80. Journal of Pharmaceutical and Biomedical Analysis can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Pharmaceutical and Biomedical Analysis - www.elsevier.com/wps/product/cws_home/525434)

Our news journalists report that additional information may be obtained by contacting E.L. Shaltout, Cairo University, Fac Pharm, Center Biotechnol, Cairo 11562, Egypt. Additional authors for this research include M.A. Al-Ghobashy, F.A. Fathalla and M.Y. Salem (see also Proteins).

Keywords for this news article include: Cairo, Egypt, Africa, Cytokines, Filgrastim, Glycoproteins, Recombinant Proteins, Hematopoietic Cell Growth Factors, Recombinant Granulocyte Colony Stimulating Factor

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters